Skip to main content

Table 2 Correlations between Exo-PD-L1, soluble PD-L1 and clinicopathological features

From: Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Characteristics

N

EXO-PD-L1

N

Soluble PD-L1

Low N (%)

High N (%)

p-value

Low N (%)

High N (%)

p-value

Age (years)

   

0.528

   

0.083

 ≤ 60

38

20 (23.53)

18 (21.18)

 

24

15 (31.25)

9 (18.75)

 

 > 60

47

22 (25.88)

25 (29.41)

 

24

9 (18.75)

15 (31.25)

 

Gender

   

0.063

   

0.233

 Male

46

27 (32.94)

19 (21.18)

 

30

17 (35.42)

13 (27.08)

 

 Female

39

15 (16.47)

24 (9.41)

 

18

7 (14.58)

11 (22.92)

 

Smoking status

   

0.138

   

0.143

 Smoker

26

16 (18.82)

10 (11.77)

 

14

8 (16.67)

6 (12.50)

 

 Non-smoker

59

26 (30.59)

33 (38.82)

 

34

16 (33.33)

18 (37.50)

 

Histology

   

0.505

   

0.348

 Squamous carcinoma

12

7 (8.24)

5 (5.88)

 

5

1 (2.08)

4 (8.33)

 

 Adenocarcinoma

73

35 (41.18)

38 (44.70)

 

43

23 (47.92)

20 (41.67)

 

TNM stage

   

0.012*

   

0.140

 I

47

29 (34.12)

18 (21.18)

 

29

17(37.50)

12 (22.92)

 

 II/III/IV

38

13 (15.29)

25 (29.41)

 

19

7 (12.50)

12 (27.08)

 

Tumor size (cm)

   

0.003**

   

0.004**

 ≤ 2.5

43

28 (32.94)

15 (17.65)

 

26

18 (37.50)

8 (16.67)

 

 > 2.5

42

14 (16.47)

28 (32.94)

 

22

6 (12.50)

16 (33.33)

 

Lymph node status

   

0.031*

   

0.131

 N0

53

31 (36.47)

22 (25.88)

 

31

18 (37.50)

13 (27.08)

 

 N1–3

32

11 (12.94)

21 (24.71)

 

17

6 (12.50)

11 (22.92)

 

Distant metastasis

   

0.026*

   

0.220

 M0

73

40 (47.06)

33 (38.82)

 

41

22 (45.83)

19 (39.58)

 

 M1

12

2 (2.35)

10 (11.77)

 

7

2 (4.17)

5 (10.42)

 
  1. * p < 0.05, ** p < 0.01